Select News

Oct 31 2014

Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals

Oct 31 2014

BOSTON, Oct. 30, 2014 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) and Transcept Pharmaceuticals, Inc. (Nasdaq:TSPT) (through October 30) today announced the two companies have completed their merger effective as of October 30, 2014.

Immediately prior to the merger, Paratek received gross proceeds of $93 million in new investment from a combination of certain current and new investors in Paratek, including Abingworth LLP, Aisling Capital, The Baupost Group, HBM Healthcare Investments, Interwest Ventures, Omega Funds, Roumell Asset Management and other highly regarded institutional investors. Together with approximately $14 million in available, pre-merger cash on Transcept’s balance sheet, the combined company has approximately $108 million in cash available before the payment of transaction and other fees.

READ MORE

Oct 27 2014

Syros Pharmaceuticals Closes $53 Million Series B Financing

Oct 27 2014

WATERTOWN, MA, October 27, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies in cancer and other diseases, announced today that it has closed its Series B round with $53 million in new investment. The proceeds from this financing will be used to advance the company’s portfolio of cancer programs towards the clinic and to expand its gene control product engine into new therapeutic areas.

READ MORE

Oct 6 2014

Actavis to Acquire Durata Therapeutics, Inc.

Oct 6 2014

DUBLIN, Ireland and CHICAGO, Oct. 6, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, today announced that they have entered into a definitive merger agreement under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23.00 per share in cash, or approximately $675 million in the aggregate, and contingent value rights (CVRs) entitling the holder to receive additional cash payments of up to $5.00 per share if certain regulatory or commercial milestones related to Durata’s lead product DALVANCETM are achieved.  Actavis expects the acquisition to be accretive by the end of the first year.

READ MORE

Oct 2 2014

Dermira Prices Initial Public Offering

Oct 2 2014

REDWOOD CITY, Calif., October 2, 2014 – Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a price to the public of $16.00 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM. In addition, Dermira has granted the underwriters a 30 day option to purchase up to an additional 1,171,875 shares of common stock to cover over-allotments, if any. Concurrently with the offering, Dermira is also selling through a private placement 468,750 shares of its common stock to UCB S.A., an existing stockholder, at the initial public offering price.

READ MORE

Oct 1 2014

Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia

Oct 1 2014

ANN ARBOR, Mich.–(BUSINESS WIRE)– Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-008, a Phase 2b study evaluating the efficacy and safety of ETC-1002 monotherapy compared with ezetimibe monotherapy in patients with hypercholesterolemia, with or without statin intolerance.

READ MORE

Sep 29 2014

Daiichi Sankyo to Acquire Ambit Biosciences

Sep 29 2014

TOKYO and SAN DIEGO, Sept. 29, 2014 /PRNewswire/ — Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences (NASDAQ: AMBI), jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.  In addition to the upfront cash payment, each Ambit Biosciences stockholder will receive one Contingent Value Right (CVR), entitling the holder to receive an additional cash payment of up to $4.50 for each share they own if certain commercialization related milestones are achieved. The total transaction is valued at up to $410 million on a fully diluted basis.

READ MORE

Sep 16 2014

Agile Initiates Phase 3 SECURE Study for Twirla™

Sep 16 2014

PRINCETON, N.J., Sept. 16, 2014 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc., (Nasdaq:AGRX) a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the initiation of its Phase 3 study called SECURE (Study to Evaluate Contraceptive Use, Reliability and Effectiveness). The SECURE study is designed to assess the efficacy, safety and tolerability of Agile’s investigational once-weekly transdermal contraceptive patch, Twirla™ (AG200-15). Twirla will be the only low-dose combined hormonal contraceptive patch and delivers the active ingredients ethinyl estradiol and levonorgestrel, both of which have an established history of efficacy and safety in currently marketed combination low-dose oral contraceptives.

READ MORE

Aug 27 2014

New Insights on Breast Cancer Research (Video)

Aug 27 2014

With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline. This potential new treatment option for breast cancer could eliminate estrogen receptors from cells and potentially redefine the standard of care for hormone receptor positive cancer, one of the most common types of cancer in women.

READ MORE

Aug 14 2014

SafeStitch Medical Announces Definitive Agreement to Merge with TransEnterix

Aug 14 2014

MIAMI & RESEARCH TRIANGLE, N.C.–(BUSINESS WIRE)–August 14, 2013–
SafeStitch Medical, Inc. (OTCBB: SFES), today announced that it has entered into a definitive agreement to merge with TransEnterix, Inc., a privately-held, medical device company with advanced technology in the use of flexible devices and robotics for minimally invasive surgery.

READ MORE

Jul 1 2014

Seragon Pharmaceuticals Announces Acquisition Agreement with Genentech

Jul 1 2014

Seragon Pharmaceuticals Inc., a leader in developing drugs for hormone dependent cancers, today announced a definitive agreement with Genentech, a member of the Roche Group, (SIX: RO, ROG; OTCQX: RHHBY) whereby Seragon will be acquired for $725 million in cash up front along with $1.0 billion in contingent development milestone payments that could bring the total transaction value to $1.725 billion. The acquisition includes Seragon’s entire SERD program, including its most advanced compound, ARN-810, a next generation SERD that is currently being evaluated in a Phase I trial in patients with estrogen receptor positive (ER+) metastatic breast cancer.

READ MORE